Newswise — Writing in the February 27 online issue of Science Signaling, researchers at University of California San Diego School of Medicine and Moores Cancer Center describe how a signaling protein that normally suppresses tumors can be manipulated (or re-programmed) by growth factors, turning it into a driver of malignant growth and metastasis.
In the lives of cells, complex communications carrying proteins and other molecules along signaling pathways dictate cellular function and well-being. But in cancer cells, communications are often massively dysregulated. “Although the multiple signaling pathways in cells are typically conceptualized as independent entities, it is their complex crosstalk that shapes many aspects of cancer,” said senior author Pradipta Ghosh, MD, professor of medicine and cellular and molecular medicine at UC San Diego School of Medicine.
Building upon earlier work published in 2015, Ghosh and colleagues investigated a protein called Disheveled-associating protein or Daple, which is produced by nearly all healthy cells in the body and is well-recognized for its role in helping cells in different tissues coordinate processes, such as development and maintenance of organs.
In their earlier work, the research team reported for the first time that Daple appeared to exert some control over the initiation and progression of colorectal cancer by suppressing tumor formation, but when cells escaped the main tumor and began circulating in the blood stream, the protein made cancer cells more invasive and more likely to spread.
At the time, however, it was not clear how the tumor suppressor could turn rogue. In their new work, the team found the culprit: an overabundance of growth factors in the tumor microenvironment.
The Wnt signaling pathway in cells is fundamental in embryonic development, helping direct the organization of cells, their functions and their fates. Later, it is essential for tissue homeostasis or equilibrium.
Normally Daple, which operates within the Wnt pathway, serves to prevent abnormal growth and stays bound to the protein Disheveled, which acts as a brake on Daple. But as normal tissue becomes cancerous, rising levels of different types of growth factors hijack this system, disengaging Disheveled from Daple, disabling the brake and unleashing Daple. Instead of suppressing tumors, Daple begins to promote tumor growth and spread. The researchers found that in colon cancers in which Daple is highly expressed with concomitant high growth factor signaling, there was a high risk for tumor recurrence compared to all other tumors.
“This work not only brings out the complexity of crosstalk between major signals that drive cancers, but also defines how such crosstalk triggers a Jekyll-to-Hyde transition in Daple at an atomic level, and what that means for patients,” said Ghosh.
Because Daple is expressed in almost all normal tissues, the researchers are optimistic that future work will reveal its impact in other cancers. In fact, Daple’s role in ovarian and gastric cancers has already been demonstrated.
“Going forward, we strive to understand what other factors trigger a Jekyll-to-Hyde transition in Daple and how we can anticipate, detect and prevent such a transition,” Ghosh said. “For a protein that first goes away during normal-to-cancer transition only to return later during cancer spread, Daple plays a sophisticated game of hide-and-seek and exemplifies the complexity in cancers.”
Co-authors on this study include: Nicolas Aznar, Jason Ear, Ying Kunkel, Nina Sun, Kendall Satterfield, Fang He, Nicholas A. Kalogriopoulos, Inmaculada Lopez-Sanchez, Majid Ghassemian, Debashis Sahoo and Irina Kufareva, all at UC San Diego.
Funding for this research came, in part, from the National Institutes of Health (CA100768, CA160911, DK099226, T32CA067764, GM071872, AI118985, GM117424, R00CA151673, F31CA206426), the American Cancer Society (ACS-IRG 70-002), Padres Pedal the Cause (PTC 2017), American Heart Association (14POST20050025), State Scholarship Fund of China Scholarship Council (201208510048), West China Hospital, Sichuan University and Bladder Cancer Advocacy Network (BCAN286601).